{"pmid":32360995,"title":"No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease.","text":["No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease.","J Hepatol","Biquard, Louise","Valla, Dominique","Rautou, Pierre-Emmanuel","32360995"],"journal":"J Hepatol","authors":["Biquard, Louise","Valla, Dominique","Rautou, Pierre-Emmanuel"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360995","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jhep.2020.04.035","keywords":["covid-19","coronavirus","nafld","liver","steatosis"],"topics":["Mechanism"],"weight":1,"_version_":1666138495929810944,"score":9.490897,"similar":[{"pmid":32387073,"title":"Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease'.","text":["Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease'.","J Hepatol","Ji, Dong","Qin, Enqiang","Xu, Jing","Zhang, Dawei","Cheng, Gregory","Wang, Yudong","Lau, George","32387073"],"journal":"J Hepatol","authors":["Ji, Dong","Qin, Enqiang","Xu, Jing","Zhang, Dawei","Cheng, Gregory","Wang, Yudong","Lau, George"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387073","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jhep.2020.04.039","weight":0,"_version_":1666428892756312064,"score":137.46112},{"pmid":32486188,"title":"SARS-CoV-2 Infection and the Liver.","text":["SARS-CoV-2 Infection and the Liver.","A novel strain of coronoviridae (SARS-CoV-2) was reported in Wuhan China in December 2019. Initially, infection presented with a broad spectrum of symptoms which typically included muscle aches, fever, dry cough, and shortness of breath. SARS-CoV-2 enters cells via ACE2 receptors which are abundant throughout the respiratory tract. However, there is evidence that these receptors are abundant throughout the body, and just as abundant in cholangiocytes as alveolar cells, posing the question of possible direct liver injury. While liver enzymes and function tests do seem to be deranged in some patients, it is questionable if the injury is due to direct viral damage, drug-induced liver injury, hypoxia, or microthromboses. Likely, the injury is multifactoral, and management of infected patients with pre-existing liver disease should be taken into consideration. Ultimately, a vaccine is needed to aid in reducing cases of SARS-CoV-2 and providing immunity to the general population. However, while considering the types of vaccines available, safety concerns, particularly of RNA- or DNA-based vaccines, need to be addressed.","Pathogens","Morgan, Katie","Samuel, Kay","Vandeputte, Martin","Hayes, Peter C","Plevris, John N","32486188"],"abstract":["A novel strain of coronoviridae (SARS-CoV-2) was reported in Wuhan China in December 2019. Initially, infection presented with a broad spectrum of symptoms which typically included muscle aches, fever, dry cough, and shortness of breath. SARS-CoV-2 enters cells via ACE2 receptors which are abundant throughout the respiratory tract. However, there is evidence that these receptors are abundant throughout the body, and just as abundant in cholangiocytes as alveolar cells, posing the question of possible direct liver injury. While liver enzymes and function tests do seem to be deranged in some patients, it is questionable if the injury is due to direct viral damage, drug-induced liver injury, hypoxia, or microthromboses. Likely, the injury is multifactoral, and management of infected patients with pre-existing liver disease should be taken into consideration. Ultimately, a vaccine is needed to aid in reducing cases of SARS-CoV-2 and providing immunity to the general population. However, while considering the types of vaccines available, safety concerns, particularly of RNA- or DNA-based vaccines, need to be addressed."],"journal":"Pathogens","authors":["Morgan, Katie","Samuel, Kay","Vandeputte, Martin","Hayes, Peter C","Plevris, John N"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486188","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/pathogens9060430","keywords":["covid-19","sars-cov-2","drug induced liver injury","liver","microthromboses","viral damage"],"locations":["Wuhan","China","hypoxia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433617899521,"score":89.19652},{"pmid":32436622,"title":"Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients.","text":["Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients.","BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients. METHODS: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (+/-5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis. RESULTS: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions. CONCLUSIONS: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease.","J Gastroenterol Hepatol","Gao, Feng","Zheng, Kenneth I","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Chen, Yong-Ping","George, Jacob","Zheng, Ming-Hua","32436622"],"abstract":["BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients. METHODS: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (+/-5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis. RESULTS: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions. CONCLUSIONS: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease."],"journal":"J Gastroenterol Hepatol","authors":["Gao, Feng","Zheng, Kenneth I","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Chen, Yong-Ping","George, Jacob","Zheng, Ming-Hua"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436622","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jgh.15112","keywords":["covid-19","metabolic associated fatty liver disease","non-diabetes"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667521393682546688,"score":89.13587},{"pmid":32352224,"title":"SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19.","text":["SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19.","Zhang et al. showed that COVID-19 affected patients' present liver biochemistry abnormalities, including elevation of aminotransferases, gamma-glutamyl transferase, and alkaline phosphatase (1) . Hence, several possible clinical scenarios in the setting of liver diseases have been postulated. First, patients with chronic liver disease may be more vulnerable to the severe clinical consequences of COVID-19, including oxygen desaturation and hypoxemia due to severe pneumonia or the cytokine storm (1;2) . Second, liver biochemistry abnormalities are the consequence of drug toxicity.","Liver Int","Pirola, Carlos J","Sookoian, Silvia","32352224"],"abstract":["Zhang et al. showed that COVID-19 affected patients' present liver biochemistry abnormalities, including elevation of aminotransferases, gamma-glutamyl transferase, and alkaline phosphatase (1) . Hence, several possible clinical scenarios in the setting of liver diseases have been postulated. First, patients with chronic liver disease may be more vulnerable to the severe clinical consequences of COVID-19, including oxygen desaturation and hypoxemia due to severe pneumonia or the cytokine storm (1;2) . Second, liver biochemistry abnormalities are the consequence of drug toxicity."],"journal":"Liver Int","authors":["Pirola, Carlos J","Sookoian, Silvia"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352224","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/liv.14500","keywords":["ace2","covid-19","furin","sars-cov-2","tmprss2","host","liver","single-cell transcriptomics"],"topics":["Mechanism"],"weight":1,"_version_":1666138495656132611,"score":85.546005},{"pmid":32414813,"title":"Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.","text":["Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.","Gut","Targher, Giovanni","Mantovani, Alessandro","Byrne, Christopher D","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Zheng, Kenneth I","Chen, Yong-Ping","Eslam, Mohammed","George, Jacob","Zheng, Ming-Hua","32414813"],"journal":"Gut","authors":["Targher, Giovanni","Mantovani, Alessandro","Byrne, Christopher D","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Zheng, Kenneth I","Chen, Yong-Ping","Eslam, Mohammed","George, Jacob","Zheng, Ming-Hua"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414813","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1136/gutjnl-2020-321611","keywords":["nonalcoholic steatohepatitis"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666994545936564224,"score":80.72174}]}